Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: International IP
-
By Donald Zuhn — Earlier this month, Science Progress, a semi-annual journal published by the Center for American Progress, issued a series of reports on the U.S. patent system. The series, outlined in an article entitled: "Patent Reform 101," consists of four reports: • "Tackling the Challenge of Patent Reform: Recommendations for the Obama…
-
By Kevin E. Noonan — Intellectual property rights (particularly Western intellectual property rights) were intended to receive improved protection under the Trade-related Aspects of Intellectual Property Rights (TRIPS) provisions of the General Agreement on Tariffs and Trade (GATT). The World Trade Organization (WTO) was to provide the forum for disputes arising under TRIPS. However,…
-
By Kevin E. Noonan — The recent changes in Chinese patent law have not received universal approval from a number of Western groups. Two of these, the Intellectual Property Owners Association (IPO) and the Biotechnology Industry Organization, have taken different tacks to the same end: disapproval of changes seen as harming their members' interests.…
-
By Kevin E. Noonan — One of our foreign associates in China, Vivien Chan & Co., informs us of a number of important changes in Chinese patent law adopted by the People's Congress on December 27th. The following new rules for patent practice will come into force in China on October 1, 2009: • …
-
By Donald Zuhn — Reflecting upon the events of the past twelve months, Patent Docs presents its second annual list of top biotech/pharma stories. For 2008, we identified a baker's dozen of top stories covered on Patent Docs. Today we will count down stories #13 to #10. On Sunday, we will present stories #9…
-
By Kevin E. Noonan — The Enlarged Board of the European Patent Office issued its decision denying a European patent on European Patent Application No. 96903521.1 (EP 0 770 125) to the Wisconsin Alumni Research Foundation (WARF), directed to human embryonic stem cells (hESCs). This decision is another example of European antipathy to biotechnology…
-
By Donald Zuhn — Last Friday, the European Commission published a 426-page preliminary report regarding its competition inquiry into the European pharmaceutical sector. The Commission commenced the sector inquiry last January to examine why fewer new medicines were being brought to market in Europe and why generic entry seemed to be delayed in some…
-
By Donald Zuhn — Earlier this month, several European news outlets reported on a decision by the UK High Court of Justice declaring a Human Genome Sciences (HGS) patent disclosing the nucleotide and amino acid sequence of Neutrokine-alpha, a novel member of the TNF ligand superfamily, to be invalid. The High Court agreed…
-
By Kevin E. Noonan — Last Friday, the European Patent Office revoked (in its entirety) European Patent No. EP 1 230 375, owned by Cancer Research Therapeutics Ltd. of Cambridge, UK and exclusively licensed to Alnylam Pharmaceuticals, Inc. The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis…
-
By Kevin E. Noonan — Two of the leaders among developing countries in challenging Western assumptions behind the TRIPS agreement and the WTO, Brazil and India, recently announced a further evolution of their national laws directed to implementing the provisions of that treaty. Brasil’s announcement concerns the administrative procedures governing the interaction between…
Patent Docs 